← Leaderboards
Peter Goldstein
Iliad Biotechnologies, Llc
$486,037
Attributed
$972,074
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $329.3K · FY2022–24$500K$375K$250K$125K$0
'22
'23
'24
Funding mix
By agency
NIH$972,074 · 1
By mechanism
R61$972,074 · 1
Top collaborators
- Camille Locht3 shared
Most similar at Iliad Biotechnologies, Llc
Same institution · by research overlap
- Camille Locht$486,037
Others in their field
Other Rising Stars on “Adolescent”
- Christine W Hockett · Avera Mckennan$8,908,366
- Michael E. Roth · Public Health Institute$8,201,777
- Henry Sachs · Emma Pendleton Bradley Hospital$7,940,991
- Matthew Morrow Engelhard · Duke University$7,519,665
- Bhaven Mehta$7,276,100
- Michael Hogarth · University Of California, San Diego$5,162,770
Research focus
AdolescentAnimal ModelAntibodiesAdultAttenuatedAttenuated VaccinesBacteriaBacterial VectorAntigensBordetella PertussisCd8-Positive T-LymphocytesCellsCell SeparationChimeric ProteinsClinical DevelopmentClinically RelevantClinical TranslationCodon NucleotidesComplementCostDendritic CellsDeveloping CountriesDiscriminationDna Cassette
Grant awards (3)
Live nasal recombinant B. pertussis vaccine against tuberculosis$317,504
R61 · FY2024 · AI · contact PI
Live nasal recombinant B. pertussis vaccine against tuberculosis$325,310
R61 · FY2023 · AI · contact PI
Live nasal recombinant B. pertussis vaccine against tuberculosis$329,260
R61 · FY2022 · AI · contact PI